CanVirex AG
CanVirex AG is a Swiss biotech company developing next‑generation cancer immuno‑virotherapies for solid tumors. As a spin‑off from Heidelberg University Hospital, CanVirex leverages a proven measles vaccine vector to deliver immunotherapeutics. The platform is supported by promising preclinical findings and early clinical experience from compassionate‑use settings, supporting further development.
Date, time and room information
Monday, May 4, 16:00 - 16:15, room Montreal
Category
Clinical stage development company
Title of the presentation
CanVirex AG – A Platform Approach to Solid Tumor Immunotherapy
Speaker information
| Name | Position | Institution |
|---|---|---|
| Dr. Tobias Starzmann | COO | CanVirex AG |
Host and event manager:
Logistics and marketing partner:
